HelsenDin.Org

Study: EP4 agonist may reduce gastric bleeding and inflammation

November 08, 2017

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 30+ different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense?, IntegriSense(TM), AngioSense(TM), OsteoSense?, Annexin-Vivo(TM), MMPSense(TM), Cat B FAST(TM), Cat K FAST(TM) and ReninSense(TM) FAST. VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag? fluorescence labeling dyes for custom agent development, and its NanoSpark? labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new OsteoSense? 800 and VivoTag? 800 agents, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

SOURCE VisEn Medical Inc.